Pradefovir in naive or experienced adult patients with chronic infection of hepatitis B virus: week24 results from 23 multicentre, double-blind, randomised, non-inferiority, phase2 trials

Yanhang Gao(Jilin University), Junqi Niu(Jilin University), Jia Shang(European Foundation for the Study of Chronic Liver Failure), Wen Chen(Fujian Medical University), Qingjing Zhu(Huazhong University of Science and Technology), Jinyu Xia(Sun Yat-sen University), Xiuhong Wen, Ting-Chun Wang, Daidi Wang, Zhenjing Jin(Second Affiliated Hospital of Jilin University), Bo Tan(Unity Health Toronto), Dengke Zhang(Wenzhou Medical University), Yanhua Ding, Liang Chen(Qingdao Agricultural University), Yongfeng Yang(Shenyang Agricultural University), Guangming Li(Shandong Iron and Steel Group (China)), Weidong Liu(National University of Defense Technology), Tao Han(Anhui University), Xiaolu Wu, Xinwen Song(First Affiliated Hospital of Xinxiang Medical University), Huanyu Gong(Central South University), Yanzhong Peng(Peking University Shenzhen Hospital), Fei Kong(Shanghai Jiao Tong University), Zong Zhang(Jinan Infectious Disease Hospital), Hesong Cui, Mao Mu(Guiyang Medical University), Xuebing Yan(Xuzhou Medical College), Caiyan Zhao(Hebei Medical University), Weili Jin, Peng Wang(Qingdao University), Qianguo Mao(Army Medical University), Lvfeng Yao
Journal of Hepatology
August 1, 2020
Cited by 0


Related Papers